Physician profile
David Anthony Ramos
NPI 1003091976
$3,105.97
in general payments reported to CMS, 2019-2025
36 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $673 · 2021: $499 · 2022: $449 · 2023: $446 · 2024: $341 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $380.10 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $336.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $266.17 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $252.71 | 2019-2020 | |
| Abbvie INC. | $243.30 | 2020-2023 | |
| Abbott Laboratories | $214.91 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $193.52 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Amarin Pharma, INC. | $181.15 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $175.17 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $110.20 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.99 | 2022 | |
| Dexcom, INC. | $73.61 | 2024-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $52.19 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.46 | 2023-2024 | Caplyta |
| Acella Pharmaceuticals, LLC | $42.94 | 2024-2025 | NP Thyroid 60 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.65 | 2022-2025 | |
| Astellas Pharma US INC | $31.85 | 2019-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $31.06 | 2019-2020 | |
| Horizon Therapeutics Plc | $28.43 | 2020-2022 | |
| Philips North America LLC | $24.20 | 2024 | (Ck7) Extended Holter |
| Janssen Biotech, INC. | $23.95 | 2019 | |
| Almatica Pharma LLC | $22.07 | 2025 | Loreev Xr |
| Ultragenyx Pharmaceutical INC. | $21.97 | 2022 | |
| Arbor Pharmaceuticals, INC. | $21.49 | 2021 | |
| Amgen INC. | $20.11 | 2025 | Repatha |
| Acerus Pharmaceuticals Corporation | $19.74 | 2022 | |
| Sanofi Pasteur INC. | $19.65 | 2022 | |
| Pfizer INC. | $19.32 | 2024 | |
| Medtronic, INC. | $19.24 | 2023 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $18.25 | 2020 | |
| Currax Pharmaceuticals LLC | $17.54 | 2024 | Contrave |
| Si-Bone, INC. | $15.85 | 2024 | |
| Intuity Medical INC | $15.12 | 2022 | |
| Dermira, INC. | $14.83 | 2020 | |
| Clarus Therapeutics INC. | $14.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.